recombinant human trail r2  (ACROBiosystems)

Journal: Nature Nanotechnology

Article Title: A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns

doi: 10.1038/s41565-024-01676-4

Figure Lengend Snippet: a , Experimental setup of cancer cell treatment with Cy5-labelled origami at pH 7.4 or 6.5. b , The Cy5 signal of SK-BR-3 cells treated with 5 nM empty origami, PEG_pH_O 6p at pH 7.4 or 6.5, measured by flow cytometry. c , Localization of Cy5-labelled origamis (magenta) relative to DR5 (cyan; detected using Alexa488-labelled anti-DR5 monoclonal antibody) on SK-BR-3 cells. The co-localization of the magenta and cyan is shown in grey. Maximum intensity projections from z -stacks. Scale bars, 20 μm.

Article Snippet: The DR5 analyte (R&D Systems, 10140-T2) was diluted from 516 nM to 32.25 nM and injected as a single-cycle kinetics experiment, with a flow rate of 30 µl min −1 , and 500 s contact time for each concentration.

Techniques: Flow Cytometry

Journal: PLoS ONE

Article Title: Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines

doi: 10.1371/journal.pone.0094438

Figure Lengend Snippet: (A)Flow cytometric analysis of TRAIL-R2 expression of T98G and U251 cells grown for 24 h in the absence (NT) or in the presence of 10 µM salinomycin (Sal). (B) Western blot showing protein levels of TRAIL-R2 in U251 cells after treatment for the indicated time with TRAIL, salinomycin (Sal), TRAIL+salinomycin (TRAIL+Sal) and TRAIL+salinomycin+zVAD.

Article Snippet: Recombinant human TRAIL (rh superkiller TRAIL) was purchased from Alexis Co (Alexis, Co, Lausen, Switzerland) and recombinant human soluble TRAIL-R2 was purchased from Peprotech (Peprotech, Rocky Hill, NJ, USA).

Techniques: Expressing, Western Blot

Journal: PLoS ONE

Article Title: Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines

doi: 10.1371/journal.pone.0094438

Figure Lengend Snippet: T98G (left panels) and U251 (right panels) cells have been incubated for 72 h either with siRNA C or siRNA TRAIL-R1 or siRNA TRAIL-R2 and then incubated for additional 24 hours either in the absence of additives (Control, C) or in the presence of either salinomycin (10 µM) or TRAIL (50 ng/ml) or both compounds at the above doses. At the end of this time the cells have been recovered and evaluated for TRAIL-R2 expression (top panels) by flow cytometry or for the cell survival (middle panels) by cell counting after trypan blue staining or for the evaluation of cell death (assayed by flow cytometry after labelling with annexin V and propidium iodide). The data reported in the figure represent mean values ± SEM observed in three separate experiments. The statistical analysis of the data showed: in top panels a very significant difference between siRNA TRAIL-R2 and si RNA C and siRNA TRAIL-R1 (for both p<0.01); in middle and bottom panels a very significant difference for both TRAIL and TRAIL+Salinomycin-treated samples between siRNA TRAIL-R2 and siRNA C (p<0.01) and siRNA TRAIL-R1 (p<0.01).

Article Snippet: Recombinant human TRAIL (rh superkiller TRAIL) was purchased from Alexis Co (Alexis, Co, Lausen, Switzerland) and recombinant human soluble TRAIL-R2 was purchased from Peprotech (Peprotech, Rocky Hill, NJ, USA).

Techniques: Incubation, Expressing, Flow Cytometry, Cell Counting, Staining

Journal: PLoS ONE

Article Title: Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines

doi: 10.1371/journal.pone.0094438

Figure Lengend Snippet: A and B – Glioblastoma neurosphere clones GSC1, GSC30 and GSC83 were grown for 48 hours either in the absence (C) or in the presence of either TRAIL (10 ng/ml) or Salinomycin 1 µM or Salinomycin 5 µM or Salinomycin 1 µM+TRAIL or Salinomycin 5 µM+TRAIL and the number of viable cells was determined by the quantification of cellular ATP content using the Cell Titer-Glo Luminescen Cell Viability Assay Kit (A) and the percentage of apoptotic cells by the Annexin-V binding assay (B). The results represent the mean values observed ± SEM observed in three separate experiments, each performed in duplicate. For all these treatments and for all the three neurosphere clones, the difference between the values observed for TRAIL and Salinomycin 1 µM+TRAIL or Salinomycin 5 µM+TRAIL were statistically significant (p = <0.05 or <0.01) and the values observed for Salinomycin 1 µM and Salinomycin 1 µM+TRAIL or Salinomycin 5 µM and Salinomycin 5 µM+TRAIL (p = <0.05 or <0.01) were statistically significant. (C) Flow cytometric detection of TRAIL-R2 expression in GSC1 cells grown for 24 h either in the absence or in the presence of salinomycin (1 or 5 µM). The results are expressed in terms of mean fluorescence intensity (MFI) values observed in three separate experiments (mean values±SEM). The differences between the values observed between 1 µM or 5 µM salinomycin and control are statistically significant (both p<0.01).

Article Snippet: Recombinant human TRAIL (rh superkiller TRAIL) was purchased from Alexis Co (Alexis, Co, Lausen, Switzerland) and recombinant human soluble TRAIL-R2 was purchased from Peprotech (Peprotech, Rocky Hill, NJ, USA).

Techniques: Clone Assay, Viability Assay, Binding Assay, Expressing, Fluorescence